Press Releases

The U.S. DoA testing market is set to reach USD 4.6 billion by 2030, growing at a CAGR of 9.7% during the forecast period. The stringent laws and regulations, government initiatives to curb drug abuse, increasing awareness against drug abuse, and development of advanced drug test equipment are the primary growth drivers for the U.S. DoA testing market.

The awareness regarding substance abuse is increasing in the country. However, the legalization of certain drugs has led to increased drug abuse, which is being curbed by the several initiatives taken by the government and non-government bodies. The U.S. government is promoting educational initiatives to be delivered in schools and communities, implementing overdose education and naloxone distribution programs, aggressive law enforcement efforts and supporting prescription drug monitoring programs. The government is also supporting the investment for research and development for pain management and next-generation analgesics. This is anticipated fuel the market for DoA testing in the U.S.

Among the various products such as immunoassay analyzers, chromatography instruments, breath analyzers, rapid test kits, and assay kits & reagents, the rapid test kits account for the largest share in the U.S. DoA testing industry. The high demand for these kits is primarily due to the need for easily available and accessible testing for on the spot drug abuse testing. The rapid test kits as per its name also present output in a short time thereby has higher demand in comparison to the other product category. The market for breath analyzers is expected to grow at the highest CAGR during the forecast period.

U.S. Drug of Abuse (DoA) Testing Market Segmentation and Key Players

Browse Market Insight and In-depth TOC on "U.S. Drug of Abuse (DoA) Testing Market – Analysis and Forecast (2025-2030)"

Different samples used for DoA testing include urine, saliva, hair, blood, breath, and others. Urine is majorly used for drug abuse testing since it contains parent drugs or metabolites in them, that is tested for the presence of major illicit drugs. The urine samples lead the global DOA testing market based on size. Some of the other sample type used includes tissue and sweat.

Hospitals are the largest end user for the DoA products and are also estimated to retain the largest market size during the forecast period. The category’s large size is due to the increasing number of research and drug test being conducted. The hospitals account to hold the high number of tests due to the availability of products on a large scale as compared to other end users of DOA testing. Also, the presence of number of clinicians in hospitals is larger, marking its large share over others.

Some of the key players operating in the U.S. DoA testing market are Siemens AG, Danaher Corporation, Merck KGaA, Laboratory Corporation of America Holdings, Express Diagnostics Int'l, Inc., Quest Diagnostics Inc., Waters Corporation, Abbott Laboratories, Psychemedics Corporation, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., and F. Hoffmann-La Roche AG.

U.S. DoA Testing Market Coverage

Product Insight and Forecast 2025-2030

• Immunoassay Analyzers
• Chromatography Instruments
• Breath Analyzers
• Rapid Test Kits
• Assay Kits & Reagents
• Others

Sample Type Insight and Forecast 2025-2030

• Urine
• Saliva
• Hair
• Blood
• Breath
• Others

End-User Insight and Forecast 2025-2030

• Hospitals
• Diagnostic laboratories
• On-the-spot Testing
• Forensic Laboratories
• Others